SEC Form 4 · accession 0001209191-18-036940
ALBIREO PHARMA, INC. · ALBO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martha J. Carter
Officer — Chief Regulatory Officer
Period of report
Jun 8, 2018
Accepted (ET)
Jun 11, 2018 · 4:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001322505
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $30.68 | Jun 8, 2018 | A | 30,000 | A | — | Jun 7, 2028 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1This option vests as to 25% of the shares on June 8, 2019 with the remainder vesting in equal installments on the last day of 12 consecutive calendar quarters beginning on June 30, 2019 and ending on March 31, 2022.
Remarks
Exhibit 24.1 - Power of Attorney